Literature DB >> 2728029

Molecular differences between type A botulinum neurotoxin and its toxoid.

B R Singh1, B R DasGupta.   

Abstract

The neurotoxins (seven serotypes, Mr approximately 150,000) produced by Clostridium botulinum cause the neuroparalytic disease botulism. Prophylaxis, definitive diagnosis and the only effective therapy for botulism depend, at present, on chemically detoxified form(s) of the neurotoxins, i.e. toxoids (immunogens), and the antisera raised with the immunogens. And yet, the toxoids currently used for immunization of humans and animals and for raising antibody are very crude preparations (approximately 90% impure) of the neurotoxins. Hence, the highly heterogenous toxoids were not suitable for physicochemical studies. We have detoxified a pure (greater than 99%) neurotoxin (serotype A) with formaldehyde. The native neurotoxin is composed of two subunit chains (Mr 53,000 and 97,000). The physicochemical properties of the toxoid (immunogenic in rabbits) were analyzed. The chemical modification produced inter- and intrasubunit covalent links at multiple sites and thus extensive aggregation of the neurotoxin. The secondary structure parameters (alpha-helix, beta-sheet, beta-turn and random coil) of the native protein were not significantly altered. Tertiary structure, as measured by exposure of tyrosine residues and fluorescence quantum yield of tryptophan residues, was considerably altered. The data imply that conformational (topographical) antigenic determinants may not contribute significantly to the serological property of the neurotoxin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2728029     DOI: 10.1016/0041-0101(89)90202-x

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  7 in total

1.  Effect of tetranitromethane on the biological activities of botulinum neurotoxin types A, B and E.

Authors:  M Woody; B R DasGupta
Journal:  Mol Cell Biochem       Date:  1989-02-21       Impact factor: 3.396

2.  Antigen retrieval causes protein unfolding: evidence for a linear epitope model of recovered immunoreactivity.

Authors:  Carol B Fowler; David L Evers; Timothy J O'Leary; Jeffrey T Mason
Journal:  J Histochem Cytochem       Date:  2011-04       Impact factor: 2.479

3.  Black tea extract, thearubigin fraction, counteract the effects of botulinum neurotoxins in mice.

Authors:  E Satoh; T Ishii; Y Shimizu; S Sawamura ; M Nishimura
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

4.  Thermostable llama single domain antibodies for detection of botulinum A neurotoxin complex.

Authors:  Ellen R Goldman; George P Anderson; Jerry Conway; Laura J Sherwood; Melissa Fech; BaoHan Vo; Jinny L Liu; Andrew Hayhurst
Journal:  Anal Chem       Date:  2008-10-24       Impact factor: 6.986

5.  Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.

Authors:  Herman F Staats; Jeffrey R Fielhauer; Afton L Thompson; Alice A Tripp; Ashley E Sobel; Massimo Maddaloni; Soman N Abraham; David W Pascual
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

6.  Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents.

Authors:  Jerry O Conway; Laura J Sherwood; M Thelma Collazo; John A Garza; Andrew Hayhurst
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

7.  A novel role of C-terminus in introducing a functionally flexible structure critical for the biological activity of botulinum neurotoxin.

Authors:  Thomas M Feltrup; Kruti Patel; Raj Kumar; Shuowei Cai; Bal Ram Singh
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.